SpringWorks Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 0.63
Market capitalization 1.47B
Operating cash flow -153.68M
ESG Scores unknown

Company description

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 491k 1.88M -1.3M 2.07M
Total Cashflows From Investing Activities -293k -4.26M -418.83M 83.59M
Net Borrowings
Total Cash From Financing Activities 50.38M 333.71M 270.49M 1.16M
Change To Operating Activities 2.07M 3.07M 2.65M 3.04M
Issuance Of Stock 169.75M 169.75M 270.49M 1.16M
Net Income -17.81M -58.31M -45.57M -173.91M
Change In Cash 35.92M 282M -180.54M -43.13M
Effect Of Exchange Rate
Total Cash From Operating Activities -14.17M -47.44M -32.19M -127.88M
Depreciation 17k 192k 349k 490k
Change To Account Receivables
Other Cashflows From Financing Activities
Change To Netincome 1.07M 5.72M 11.69M 40.42M
Capital Expenditures -293k -670k -642k -2.02M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 9.9M 42.55M 51.86M 101.68M
Income Before Tax -17.81M -58.31M -45.57M -173.91M
Net Income -17.81M -58.31M -45.57M -173.91M
Selling General Administrative 8.59M 16.69M 29.46M 71.79M
Gross Profit 35M
Ebit -18.49M -59.24M -46.32M -173.47M
Operating Income -18.49M -59.24M -46.32M -173.47M
Interest Expense
Income Tax Expense
Total Revenue 35M
Cost Of Revenue
Total Other Income ExpenseNet 678k 933k 750k -442k
Net Income From Continuing Ops -17.81M -58.31M -45.57M -173.91M
Net Income Applicable To Common Shares -17.81M -50.58M -45.57M -173.91M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 4.83M 12.76M 19.13M 30.1M
Total Stockholder Equity -21.38M 322.07M 557.06M 422.4M
Other Current Liabilities 335k 363k
Total Assets 48.39M 334.83M 576.19M 452.49M
Common Stock 4k 5k 5k
Other Current Assets
Retained Earnings -22.45M -73.03M -118.6M -292.51M
Treasury Stock 41k -312k
Cash 45.65M 327.65M 147.09M 103.96M
Total Current Liabilities 3.68M 11.97M 17.61M 29.97M
Other Stockholder Equity 41k -312k
Property, Plant, and Equipment 317k 795k 3.02M 4.2M
Total Current Assets 47.03M 331.36M 513.4M 382.91M
Net Tangible Assets -21.38M 322.07M 557.06M 422.4M
Net Receivables
Accounts Payable 774k 2.65M 1.35M 3.43M


Insider Transactions

Here are the insider transactions of stock shares related to SpringWorks Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
ORBIMED ADVISORS, L.L.C.Sale at price 31.96 - 31.98 per share.I2022-09-12Beneficial Owner of more than 10% of a Class of Security153.9k
ORBIMED ADVISORS, L.L.C.Sale at price 37.47 - 38.33 per share.I2022-08-09Beneficial Owner of more than 10% of a Class of Security274.57k
ALBAN CARLOSStock Award(Grant) at price 0.00 per share.D2022-07-14Director10.06k
SMITH LESLEY MARYStock Award(Grant) at price 0.00 per share.D2022-06-30Officer6.09k
BURGESS MICHAEL FStock Award(Grant) at price 0.00 per share.D2022-06-30Officer12.19k
SQUINTO STEPHEN PStock Award(Grant) at price 0.00 per share.D2022-05-19Director and Beneficial Owner of more than 10% of a Class of Security4.82k
LYNCH DANIEL SStock Award(Grant) at price 0.00 per share.D2022-05-19Director4.82k
FUHRMAN ALANStock Award(Grant) at price 0.00 per share.D2022-05-19Director4.82k
LEWIS-HALL FREDA CStock Award(Grant) at price 0.00 per share.D2022-05-19Director4.82k
HAMBLETON JULIEStock Award(Grant) at price 0.00 per share.D2022-05-19Director4.82k
SCHWARTZ JEFFREY LAWRENCEStock Award(Grant) at price 0.00 per share.D2022-05-19Director4.82k
FRANCIS PERIER I. JR.Stock Award(Grant) at price 0.00 per share.D2022-01-06Chief Financial Officer18.81k
WEINSTEIN HERSCHEL SStock Award(Grant) at price 0.00 per share.D2022-01-06General Counsel13.06k
ISLAM SAQIBStock Award(Grant) at price 0.00 per share.D2022-01-06Chief Executive Officer78.37k
NOFI MICHAELStock Award(Grant) at price 0.00 per share.D2022-01-06Officer5.75k
SMITH LESLEY MARYStock Award(Grant) at price 0.00 per share.D2022-01-06Officer22.2k
EDRIS BADREDDINStock Award(Grant) at price 0.00 per share.D2022-01-06Chief Operating Officer26.12k
BURGESS MICHAEL FStock Award(Grant) at price 0.00 per share.D2022-01-06Officer15.67k
PICHL DANIELStock Award(Grant) at price 0.00 per share.D2022-01-06Officer13.06k
ASHAR BHAVESHStock Award(Grant) at price 0.00 per share.D2022-01-06Officer13.06k
ISLAM SAQIBSale at price 58.67 per share.D2021-10-20Chief Executive Officer10.08k
ISLAM SAQIBSale at price 58.59 - 58.81 per share.D2021-10-19Chief Executive Officer52.42k
SMITH LESLEY MARYSale at price 55.97 per share.D2021-10-13Officer10k
SMITH LESLEY MARYConversion of Exercise of derivative security at price 2.30 per share.D2021-10-13Officer10k
PICHL DANIELConversion of Exercise of derivative security at price 43.10 per share.D2021-09-08Officer2.32k
BAIN CAPITAL LIFE SCIENCES INVESTORS, L.L.C.Sale at price 70.25 per share.I2021-08-10Beneficial Owner of more than 10% of a Class of Security1M
ISLAM SAQIBSale at price 76.09 - 77.68 per share.D2021-07-20Chief Executive Officer62.5k
SMITH LESLEY MARYSale at price 80.88 per share.D2021-07-13Officer10k
SMITH LESLEY MARYConversion of Exercise of derivative security at price 2.30 per share.D2021-07-13Officer10k
ORBIMED ADVISORS, L.L.C.Sale at price 85.01 per share.I2021-07-01Beneficial Owner of more than 10% of a Class of Security15.96k
EDRIS BADREDDINSale at price 85.35 per share.D2021-07-01Chief Operating Officer32k
ORBIMED ADVISORS, L.L.C.Sale at price 85.17 per share.I2021-06-28Beneficial Owner of more than 10% of a Class of Security6.5k
ORBIMED ADVISORS, L.L.C.Sale at price 85.00 - 85.22 per share.I2021-06-25Beneficial Owner of more than 10% of a Class of Security56.63k
ORBIMED ADVISORS, L.L.C.Sale at price 85.09 per share.I2021-06-10Beneficial Owner of more than 10% of a Class of Security30.85k
ORBIMED ADVISORS, L.L.C.Sale at price 84.90 - 85.37 per share.I2021-06-09Beneficial Owner of more than 10% of a Class of Security48.05k
BURGESS MICHAEL FStock Award(Grant) at price 0.00 per share.D2021-06-01Officer27.5k
SQUINTO STEPHEN PStock Award(Grant) at price 0.00 per share.D2021-05-20Director and Beneficial Owner of more than 10% of a Class of Security1.11k
LYNCH DANIEL SStock Award(Grant) at price 0.00 per share.D2021-05-20Director1.11k
FUHRMAN ALANStock Award(Grant) at price 0.00 per share.D2021-05-20Director1.11k
LEWIS-HALL FREDA CStock Award(Grant) at price 0.00 per share.D2021-05-20Director1.11k
HAMBLETON JULIEStock Award(Grant) at price 0.00 per share.D2021-05-20Director1.11k
SCHWARTZ JEFFREY LAWRENCEStock Award(Grant) at price 0.00 per share.D2021-05-20Director and Beneficial Owner of more than 10% of a Class of Security1.11k
SQUINTO STEPHEN PSale at price 75.05 - 76.20 per share.D2021-04-28Director and Beneficial Owner of more than 10% of a Class of Security19.43k
ISLAM SAQIBSale at price 66.39 - 69.04 per share.D2021-04-20Chief Executive Officer62.5k
SQUINTO STEPHEN PSale at price 75.01 - 75.08 per share.D2021-04-15Director and Beneficial Owner of more than 10% of a Class of Security1.57k
SMITH LESLEY MARYSale at price 68.07 per share.D2021-04-13Officer10k
SMITH LESLEY MARYConversion of Exercise of derivative security at price 2.30 per share.D2021-04-13Officer10k
ASHAR BHAVESHStock Award(Grant) at price 0.00 per share.D2021-04-01Officer12.5k
BAIN CAPITAL LIFE SCIENCES INVESTORS, L.L.C.Sale at price 71.50 per share.I2021-03-09Beneficial Owner of more than 10% of a Class of Security1.45M
ORBIMED ADVISORS, L.L.C.Sale at price 83.19 per share.I2021-03-01Beneficial Owner of more than 10% of a Class of Security1.22M
EDRIS BADREDDINSale at price 84.07 per share.D2021-01-25Chief Operating Officer32k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to SpringWorks Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on SpringWorks Therapeutics Inc

Here is the result of two systematic investment strategies applied to SpringWorks Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on SpringWorks Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to SpringWorks Therapeutics Inc:

SpringWorks Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 67.25% on the backtest period.

Performance at glance

Performance

67.25 %

Latent gain

661.7 $

Invested capital

983.9 $

Annualized return

32.02 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on SpringWorks Therapeutics Inc

This is the result of two momentum investment strategies applied to SpringWorks Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on SpringWorks Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on SpringWorks Therapeutics Inc:

SpringWorks Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 95.62% of return on SpringWorks Therapeutics Inc. That represents 2120.68$ of latent gain with 2217.72$ of employed capital.
  • The second momentum investment strategy would give 90.89% of return on SpringWorks Therapeutics Inc. That represents 890.38$ of latent gain with 979.62$ of employed capital.
Performance at glance (1Q Momentum)

Performance

95.62 %

Latent gain

2120.68 $

Invested capital

2217.72 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

90.89 %

Latent gain

890.38 $

Invested capital

979.62 $

Annualized return

56.1 %

Momentum equity curve on SpringWorks Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to SpringWorks Therapeutics Inc:

SpringWorks Therapeutics Inc momentum equity

Note: the dividends potentially given by SpringWorks Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on SpringWorks Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on SpringWorks Therapeutics Inc since the beginning:

SpringWorks Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on SpringWorks Therapeutics Inc

Buy the dip entry openings on SpringWorks Therapeutics Inc

SpringWorks Therapeutics Inc

The performance achieved by the robo-advisor on SpringWorks Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows SpringWorks Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of SpringWorks Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to SpringWorks Therapeutics Inc

The following chart shows the result of the investment strategy applied to SpringWorks Therapeutics Inc:

SpringWorks Therapeutics Inc

Note: the dividends potentially given by SpringWorks Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on SpringWorks Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on SpringWorks Therapeutics Inc:

SpringWorks Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on SpringWorks Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to SpringWorks Therapeutics Inc.

Equity curve comparison on SpringWorks Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

SpringWorks Therapeutics Inc investment strategy comparison

Employed capital comparison on SpringWorks Therapeutics Inc

SpringWorks Therapeutics Inc investment comparison

Performance comparison on SpringWorks Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 67.25% 661.7$ 983.9$ 32.02%
Momentum 1 quarter 95.62% 2120.68$ 2217.72$ 51.41%
Momentum 2 quarters 90.89% 890.38$ 979.62$ 56.1%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

32.02 %

Momentum 1Q

56.1 %

Momentum 2Q

56.1 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with SpringWorks Therapeutics Inc:

Note: The algorithm computes the probability of correlation between SpringWorks Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of SpringWorks Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name SpringWorks Therapeutics Inc
Country United States
City Stamford
Address 100 Washington Boulevard
Phone 203 883 9490
Website www.springworkstx.com
FullTime employees 222
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker SWTX
Market www.nasdaq.com

SpringWorks Therapeutics Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown